152 related articles for article (PubMed ID: 28786105)
1. Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).
Bhatia AK; Lee JW; Pinto HA; Jacobs CD; Limburg PJ; Rubin P; Arusell RM; Dunphy EP; Khandekar JD; Reiner SA; Baez-Diaz L; Celano P; Li S; Li Y; Burtness BA; Adams GL; Pandya KJ
Cancer; 2017 Dec; 123(23):4653-4662. PubMed ID: 28786105
[TBL] [Abstract][Full Text] [Related]
2. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.
Khuri FR; Kim ES; Lee JJ; Winn RJ; Benner SE; Lippman SM; Fu KK; Cooper JS; Vokes EE; Chamberlain RM; Williams B; Pajak TF; Goepfert H; Hong WK
Cancer Epidemiol Biomarkers Prev; 2001 Aug; 10(8):823-9. PubMed ID: 11489748
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
Khuri FR; Lee JJ; Lippman SM; Kim ES; Cooper JS; Benner SE; Winn R; Pajak TF; Williams B; Shenouda G; Hodson I; Fu K; Shin DM; Vokes EE; Feng L; Goepfert H; Hong WK
J Natl Cancer Inst; 2006 Apr; 98(7):441-50. PubMed ID: 16595780
[TBL] [Abstract][Full Text] [Related]
4. 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group.
Toma S; Bonelli L; Sartoris A; Mira E; Antonelli A; Beatrice F; Giordano C; Benazzo M; Caroggio A; Cavalot AL; Gandolfo S; Garozzo A; Margarino G; Schenone G; Spadini N; Sirotovà Z; Zibordi F; Balzarini F; Serafini I; Miani P; Cortesina G
Oncol Rep; 2004 Jun; 11(6):1297-305. PubMed ID: 15138569
[TBL] [Abstract][Full Text] [Related]
5. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V; Myers J; Morrison W; Gillenwater A; Ang KK; Lippman SM; Goepfert H; Hong WK
J Clin Oncol; 2001 Jun; 19(12):3010-7. PubMed ID: 11408495
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.
Lippman SM; Lee JJ; Karp DD; Vokes EE; Benner SE; Goodman GE; Khuri FR; Marks R; Winn RJ; Fry W; Graziano SL; Gandara DR; Okawara G; Woodhouse CL; Williams B; Perez C; Kim HW; Lotan R; Roth JA; Hong WK
J Natl Cancer Inst; 2001 Apr; 93(8):605-18. PubMed ID: 11309437
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.
Hildebrandt MA; Lippman SM; Etzel CJ; Kim E; Lee JJ; Khuri FR; Spitz MR; Lotan R; Hong WK; Wu X
Clin Cancer Res; 2012 Jul; 18(13):3705-13. PubMed ID: 22577058
[TBL] [Abstract][Full Text] [Related]
8. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients.
Lee JJ; Wu X; Hildebrandt MA; Yang H; Khuri FR; Kim E; Gu J; Ye Y; Lotan R; Spitz MR; Hong WK
Cancer Prev Res (Phila); 2011 Feb; 4(2):185-93. PubMed ID: 21292633
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of head and neck cancer with retinoids: a negative result.
Perry CF; Stevens M; Rabie I; Yarker ME; Cochrane J; Perry E; Traficante R; Coman W
Arch Otolaryngol Head Neck Surg; 2005 Mar; 131(3):198-203. PubMed ID: 15781758
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer.
Minard CG; Spitz MR; Wu X; Hong WK; Etzel CJ
Cancer; 2006 Jun; 106(12):2636-44. PubMed ID: 16703596
[TBL] [Abstract][Full Text] [Related]
11. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.
Urba S; van Herpen CM; Sahoo TP; Shin DM; Licitra L; Mezei K; Reuter C; Hitt R; Russo F; Chang SC; Hossain AM; Frimodt-Moller B; Koustenis A; Hong RL
Cancer; 2012 Oct; 118(19):4694-705. PubMed ID: 22434360
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients.
Bairati I; Meyer F; Gélinas M; Fortin A; Nabid A; Brochet F; Mercier JP; Têtu B; Harel F; Mâsse B; Vigneault E; Vass S; del Vecchio P; Roy J
J Natl Cancer Inst; 2005 Apr; 97(7):481-8. PubMed ID: 15812073
[TBL] [Abstract][Full Text] [Related]
14. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.
Hong WK; Lippman SM; Itri LM; Karp DD; Lee JS; Byers RM; Schantz SP; Kramer AM; Lotan R; Peters LJ
N Engl J Med; 1990 Sep; 323(12):795-801. PubMed ID: 2202902
[TBL] [Abstract][Full Text] [Related]
15. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma.
Brewster AM; Lee JJ; Clayman GL; Clifford JL; Reyes MJ; Zhou X; Sabichi AL; Strom SS; Collins R; Meyers CA; Lippman SM
J Clin Oncol; 2007 May; 25(15):1974-8. PubMed ID: 17513803
[TBL] [Abstract][Full Text] [Related]
17. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States).
Do KA; Johnson MM; Doherty DA; Lee JJ; Wu XF; Dong Q; Hong WK; Khuri FR; Fu KK; Spitz MR
Cancer Causes Control; 2003 Mar; 14(2):131-8. PubMed ID: 12749718
[TBL] [Abstract][Full Text] [Related]
18. A strong case for personalized, targeted cancer prevention.
Dawson MI
Cancer Prev Res (Phila); 2011 Feb; 4(2):173-6. PubMed ID: 21292632
[TBL] [Abstract][Full Text] [Related]
19. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up.
Benner SE; Pajak TF; Lippman SM; Earley C; Hong WK
J Natl Cancer Inst; 1994 Jan; 86(2):140-1. PubMed ID: 8271298
[No Abstract] [Full Text] [Related]
20. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
